UCD School of Medicine, College of Health and Agricultural Science, and UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e752-e768. doi: 10.1016/j.clml.2020.05.026. Epub 2020 Jun 7.
Multiple myeloma (MM) is a cancer of the plasma cells within the bone marrow (BM). Studies have shown that the cellular and noncellular components of the BM milieu, such as cytokines and exosomes, play an integral role in MM pathogenesis and progression by mediating drug resistance and inducing MM proliferation. Moreover, the BM microenvironment of patients with MM facilitates cancer tolerance and immune evasion through the expansion of regulatory immune cells, inhibition of antitumor effector cells, and disruption of the antigen presentation machinery. These are of special relevance, especially in the current era of cancer immunotherapy. An improved understanding of the supportive role of the MM BM microenvironment will allow for the development of future therapies targeting MM in the context of the BM milieu to elicit deeper and more durable responses. In the present review, we have discussed our current understanding of the role of the BM microenvironment in MM progression and resistance to therapy and discuss novel potential approaches to alter its pro-MM function.
多发性骨髓瘤(MM)是一种骨髓(BM)中浆细胞的癌症。研究表明,BM 环境中的细胞和非细胞成分,如细胞因子和外泌体,通过介导耐药性和诱导 MM 增殖,在 MM 的发病机制和进展中发挥着重要作用。此外,MM 患者的 BM 微环境通过扩增调节性免疫细胞、抑制抗肿瘤效应细胞和破坏抗原呈递机制来促进癌症耐受和免疫逃逸。这些在癌症免疫治疗的当前时代尤为重要。对 MM BM 微环境支持作用的深入了解,将有助于开发针对 BM 环境中 MM 的未来治疗方法,以产生更深层次和更持久的反应。在本综述中,我们讨论了我们目前对 BM 微环境在 MM 进展和对治疗的耐药性中的作用的理解,并讨论了改变其促 MM 功能的新的潜在方法。